机构:[1]Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China.四川大学华西医院[3]Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA.[4]Center for Genetic Medicine Research, Children’s Research Institute, Children’s National Hospital, Washington, DC 20010, USA.[5]Sarepta Therapeutics, Burlington, MA, USA.
This work was supported by the National Institute of Child Health and
Human Development P01-HD057247 (J.M.W.) and the Kettering Family Foundation (M.L.B.).
The State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan
University and the Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China
provided the salary for Y.Y.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|1 区综合性期刊
小类|1 区综合性期刊
最新[2023]版:
大类|1 区综合性期刊
小类|1 区综合性期刊
第一作者:
第一作者机构:[1]Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Lili Wang,Yang Yang,Camilo Breton,et al.A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.[J].Science advances.2020,6(7):eaax5701.doi:10.1126/sciadv.aax5701.
APA:
Lili Wang,Yang Yang,Camilo Breton,Peter Bell,Mingyao Li...&James M. Wilson.(2020).A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency..Science advances,6,(7)
MLA:
Lili Wang,et al."A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.".Science advances 6..7(2020):eaax5701